CALQUENCE plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial Read more
TAGRISSO reduces disease progression or death by 84 % in Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial Read more
AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData Read more
AstraZeneca’s DKD pipeline highlights potential to differentiate in kidney disease space: GlobalData Read more